FDA grants ODD to Keros KER-065 for treatment of Duchenne muscular dystrophy
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company is bringing precision therapies for gynaecological cancers
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
The facility will be positioned as a Centre of Excellence for tertiary care services
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Subscribe To Our Newsletter & Stay Updated